The Food and Drug Administration (FDA) announces that Clarcon Biological Chemistry Laboratory Inc. of Roy, Utah, is voluntarily recalling some skin sanitizers and skin protectants marketed under several different brand names because of high levels of disease-causing bacteria found in the product during a recent inspection. The FDA is warning consumers to not use any Clarcon products.
Consumers should not use any Clarcon products and should throw these products away in household refuse. Analyses of several samples of over-the-counter topical antimicrobial skin sanitizer and skin protectant products revealed high levels of various bacteria, including some associated with unsanitary conditions. Some of these bacteria can cause opportunistic infections of the skin and underlying tissues. Such infections may need medical or surgical attention, and may result in permanent damage. Examples of products that should be discarded include:
-- Citrushield Lotion
-- Dermasentials DermaBarrier
-- Dermassentials by Clarcon Antimicrobial Hand Sanitizer
-- Iron Fist Barrier Hand Treatment
-- Skin Shield Restaurant
-- Skin Shield Industrial
-- Skin Shield Beauty Salon Lotion
-- Total Skin Care Beauty
-- Total Skin Care Work
Findings from the FDA’s recent inspection of the Clarcon facility are particularly concerning because the products are promoted as antimicrobial agents that claim to treat open wounds, damaged skin, and protect against various infectious diseases. The inspection uncovered serious deviations from FDA’s current Good Manufacturing Practice requirements.
The Guardians of Animal Health: Who Are Veterinary Infection Preventionists?
March 21st 2025Veterinary infection control experts Leslie Kollmann, BS, AAS, CVT, CIC, Denise Waiting, LVT, and Leslie Landis, LVT, BS, discuss challenges, zoonotic disease risks, and the importance of education, collaboration, and resource development in animal care facilities.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.
Unmasking Long COVID: Dr Noah Greenspan on Recovery, Research Gaps, and the Future of Treatment
March 18th 2025Dr Noah Greenspan discusses the evolving understanding of long COVID, current treatment strategies, diagnostic challenges, and the critical need for research and awareness in post-viral syndromes.